Compare NKTX & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKTX | LNSR |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 146.7M |
| IPO Year | 2020 | 2005 |
| Metric | NKTX | LNSR |
|---|---|---|
| Price | $2.32 | $11.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $13.25 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 669.7K | 33.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,494,000.00 |
| Revenue This Year | N/A | $19.55 |
| Revenue Next Year | N/A | $35.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.87 |
| 52 Week Low | $1.31 | $9.46 |
| 52 Week High | $2.81 | $17.31 |
| Indicator | NKTX | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 43.79 |
| Support Level | $1.95 | $11.66 |
| Resistance Level | $2.47 | $12.13 |
| Average True Range (ATR) | 0.19 | 0.28 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 4.76 | 24.29 |
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.